Long-term follow-up after AAVAnc80-hOTOF gene therapy for otoferlin-related hearing loss
Follows people with otoferlin gene hearing loss who already received AAVAnc80-hOTOF gene therapy.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Boston, Iowa City, and Philadelphia, United StatesSee the 3 sitesAlso in 2 other countries, 2 sites
- Trial code
- Registry title
- Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy
- Status
- Enrolling by invitation
- Phase
- Phase 2/3
- People taking part
- 30 people, planned
- Started
- 11 Nov 2024
- Expected to end
- Apr 2033
- Type of study
- Observational
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with hearing loss caused by changes in the otoferlin gene who already received AAVAnc80-hOTOF in the AK-OTOF-101 trial. It follows their safety and hearing over a long time.
- Sex
- All sexes can join.
- Disease stage
- Sensorineural hearing loss (inner ear hearing loss) caused by otoferlin gene changes.
- Earlier treatment
- Must have received AAVAnc80-hOTOF into the inner ear (cochlea) in the AK-OTOF-101 Clinical Trial.
- Biomarker or test result
- Otoferlin gene mutations.
Main reasons for not taking part
- Any condition that would stop the person from completing the follow-up exams.
- Any condition that, in the investigator's opinion, makes the person unfit for the study.
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Individuals with otoferlin gene-mediated hearing loss who received intracochlear administration of AAVAnc80-hOTOF in the AK-OTOF-101 Clinical Trial
- Legally authorized representative and/or participant willingness to comply with all study requirements, as evidenced by successful completion of the informed consent process or permission and participant assent process (where appropriate)
Who cannot take part
- Any condition that would not allow the potential participant to complete follow-up examinations during the course of the study and/or, in the opinion of the Investigator, makes the potential participant unsuitable for the study
Where in United States
Also in 2 other countries, 2 sites
- Boston Children's HospitalBoston, United StatesEnrolling by invitation
- University of IowaIowa City, United StatesEnrolling by invitation
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This multi-center, observational, post-intervention long term follow-up (LTFU) study will monitor for safety and efficacy of AAVAnc80-hOTOF in individuals with sensorineural hearing loss due to otoferlin gene mutations who have previously received intracochlear administration of AAVAnc80-hOTOF in the AK-OTOF-101 Clinical Trial.
The group in the trial
- Study Participants
Individuals with otoferlin gene-mediated hearing loss who received intracochlear administration of AAVAnc80-hOTOF in the AK-OTOF-101 Clinical Trial
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Evaluation of the Long Term Safety and Efficacy of AAVAnc80-hOTOF Gene Therapy in Individuals With Sensorineural Hearing Loss Due to Otoferlin Gene Mutations
- Plain-language title
- Long-term follow-up after AAVAnc80-hOTOF gene therapy for otoferlin-related hearing lossGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 4 November 2026